Association of HLA class II with clinical and immune parameters
| Characteristics | HLA class II on tumor cells | HLA class II on TILs | ||||
| Negative | Positive | P value | Negative | Positive | P value | |
| Age | 1.000 | 0.133 | ||||
| <70 | 72 (91.1%) | 7 (8.9%) | 41 (51.9%) | 38 (48.1%) | ||
| ≥70 | 21 (91.3%) | 2 (8.7%) | 16 (69.6%) | 7 (30.4%) | ||
| Gender | 0.080 | 0.622 | ||||
| Female | 14 (77.9%) | 4 (22.2%) | 11 (61.1%) | 7 (38.9%) | ||
| Male | 79 (94.1%) | 5 (5.9%) | 46 (54.8%) | 38 (45.2%) | ||
| Smoking status | 1.000 | 0.065 | ||||
| Non-smoker | 53 (91.4%) | 5 (8.6%) | 37 (63.8%) | 21 (36.2%) | ||
| Smoker | 40 (90.9%) | 4 (9.1%) | 20 (45.5%) | 24 (54.5%) | ||
| T stage | 1.000 | 0.051 | ||||
| 1–2 | 79 (90.8%) | 8 (9.2%) | 45 (51.7%) | 42 (48.3%) | ||
| 3–4 | 14 (93.3%) | 1 (6.7%) | 12 (80.0%) | 3 (20.0%) | ||
| N stage | 0.494 | 0.002* | ||||
| 0 | 39 (88.6%) | 5 (11.4%) | 17 (38.6%) | 27 (61.4%) | ||
| 1–2 | 54 (93.1%) | 4 (6.9%) | 40 (69.0%) | 18 (31.0%) | ||
| M stage | 1.000 | 1.000 | ||||
| 0 | 89 (90.8%) | 9 (9.2%) | 55 (56.1%) | 43 (43.9%) | ||
| 1 | 4 (100.0%) | 0 (0.0%) | 2 (50.0%) | 2 (50.0%) | ||
| Lung cancer staging | 0.733 | 0.066 | ||||
| Stage I–II | 54 (90.0%) | 6 (10.0%) | 29 (48.3%) | 31 (51.7%) | ||
| Stage III | 39 (92.9%) | 3 (7.1%) | 28 (66.7%) | 14 (33.3%) | ||
| PD-1 on TILs | 0.028* | 0.016* | ||||
| Negative | 59 (96.7%) | 2 (3.3%) | 40 (65.6%) | 21 (34.4%) | ||
| Positive | 34 (82.9%) | 7 (17.1%) | 17 (41.5%) | 24 (58.5%) | ||
| PD-L1 on TILs | 1.000 | <0.001* | ||||
| Negative | 58 (90.6%) | 6 (9.4%) | 47 (73.4%) | 17 (26.6%) | ||
| Positive | 35 (92.1%) | 3 (7.9%) | 10 (26.3%) | 28 (73.7%) | ||
| PD-L1 on tumor cells | 1.000 | 0.318 | ||||
| Negative | 89 (90.8%) | 9 (9.2%) | 56 (57.1%) | 42 (42.9%) | ||
| Positive | 4 (100.0%) | 0 (0.0%) | 1 (25.0%) | 3 (75.0%) | ||
| CD3 | 0.495 | <0.001* | ||||
| Negative | 45 (93.7%) | 3 (6.3%) | 38 (79.2%) | 10 (20.8%) | ||
| Positive | 48 (88.9%) | 6 (11.1%) | 19 (35.2%) | 35 (64.8%) | ||
| CD4 | 0.287 | <0.001* | ||||
| Negative | 60 (93.7%) | 4 (6.3%) | 45 (70.3%) | 19 (29.7%) | ||
| Positive | 33 (86.8%) | 5 (13.2%) | 12 (31.6%) | 26 (68.4%) | ||
| CD8 | 0.466 | <0.001* | ||||
| Negative | 64 (92.8%) | 5 (7.2%) | 48 (69.6%) | 21 (30.4%) | ||
| Positive | 29 (87.9%) | 4 (12.1%) | 9 (27.3%) | 24 (72.7%) | ||
| FOXP3 | 0.268 | <0.001* | ||||
| Negative | 63 (94.0%) | 4 (6.0%) | 49 (73.1%) | 18 (26.9%) | ||
| Positive | 30 (85.7%) | 5 (14.3%) | 8 (22.9%) | 27 (77.1%) | ||
*P<0.05 indicates statistical significance.
HLA class II, human leukocyte antigen class II; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TILs, tumor infiltrating lymphocytes.